nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 29th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
990.00
|
990.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
109.00
|
About two weeks
|
111.00
|
MEDIUM
|
108.00
|
FAVORABLE
|
|
|
|
Aug 29th, 2022 01:55PM
|
Aug 29th, 2022 01:55PM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 28th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
990.00
|
990.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 28th, 2022 07:32AM
|
Aug 28th, 2022 07:32AM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 27th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
990.00
|
990.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 27th, 2022 06:21AM
|
Aug 27th, 2022 06:21AM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 25th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
989.00
|
989.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 25th, 2022 10:53AM
|
Aug 25th, 2022 10:53AM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 23rd, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
989.00
|
989.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 23rd, 2022 12:46PM
|
Aug 23rd, 2022 12:46PM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 21st, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
989.00
|
989.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 21st, 2022 02:32PM
|
Aug 21st, 2022 02:32PM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 20th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
989.00
|
989.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 20th, 2022 04:12PM
|
Aug 20th, 2022 04:12PM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 19th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
989.00
|
989.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 19th, 2022 02:31PM
|
Aug 19th, 2022 02:31PM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 18th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
65.0
|
67.0
|
69.0
|
180.0
|
989.00
|
989.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 18th, 2022 07:09AM
|
Aug 18th, 2022 07:09AM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nyse:nvo
|
https://www.indeed.com/cmp/novo-nordisk,-inc.
|
Aug 17th, 2022 12:00AM
|
Open
|
Novo Nordisk, Inc.
|
|
Pharmaceutical & Biotechnology
|
Changing diabetes. It’s a challenge that impacts the lives of hundreds of millions of people worldwide. It's a number that’s growing every day. At Novo Nordisk, it has been our focus for more than 90 years. As the world leader in diabetes research, care, and treatment, our passion for people and helping them live better lives is at the heart of everything we do.
It compels us to continually develop one of the broadest diabetes product portfolios in the healthcare industry, including innovative insulin delivery systems. In addition, we deliver innovative solutions for individuals with hemophilia and growth hormone deficiency.
With more than a decade of consistent growth and an innovative product pipeline, we know that “how” we achieve our goals is just as important as what we achieve. Our success is built on the Novo Nordisk Way. It includes our vision, our values, and our approach to the Triple Bottom Line, an unmatched commitment to financial, social, and environmental responsibility.
|
RRv1_OVER_10B
|
Plainsboro, NJ
|
Lars Fruergaard Jørgensen
|
|
|
4.10
|
70.0
|
65.0
|
70.0
|
71.0
|
65.0
|
65.0
|
61.0
|
70.0
|
61.0
|
62.0
|
|
67.0
|
69.0
|
180.0
|
989.00
|
989.00
|
3.80
|
4.10
|
3.50
|
3.50
|
3.80
|
108.00
|
About two weeks
|
109.00
|
MEDIUM
|
107.00
|
FAVORABLE
|
|
|
|
Aug 17th, 2022 11:53AM
|
Aug 17th, 2022 11:53AM
|
Novo Nordisk
|
Health Care
|
Pharmaceuticals & Biotechnology
|